Successfully producing large quantities of biotherapeutics, including monoclonal antibodies and recombinant protein products, depends on robust and reliable cell line development (CLD). Issues that ...
Advances in cell line engineering and microfluidic technologies offer substantial opportunities to shorten timelines in cell line development (CLD). However, as with any innovation, optimizing these ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback